
At Phenotypeca, we unlock the full potential of genomic diversity to power the next generation of biological products. Our proprietary QTL strain optimisation platform delivers unmatched performance in yield, cost, and regulatory readiness, while securing robust IP protection.
From biosimilars and biologic therapeutics to advanced peptides, our work delivers measurable value for partners in pharmaceuticals, consumer health, and beyond.
Backed by decades of experience and a leadership team spanning science, strategy, and commercialisation, we are building a global portfolio of differentiated biotech products—one optimised genome at a time.
